News

Emerging technology may facilitate individualized care, disease management.

The FDA has granted Fast Track designation to MeiraGTx's AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM).

Organization shines spotlight on frontline heroes during ongoing COVID-19 battle.

For ophthalmologists, practice makes perfect in becoming ambidextrous.

Ocular symptoms in COVID-19 patients may be more common than previously thought — with sore eyes a significant sign of disease.

The traditional treatment for primary angle-closure (PAC) and PAC glaucoma (PACG) is laser peripheral iridotomy (LPI) to facilitate aqueous outflow followed by medical treatment with drops to decrease the intraocular pressure (IOP).

Sunita Radhakrishnan, MD, in a presentation at the 25th annual Glaucoma Symposium at the Glaucoma 360 virtual annual event, noted that concomitant treatment of both glaucoma and dry eye is key.

In observance of International Holocaust Remembrance Day this January 27, John H. Merey, MD, may be the only Holocaust survivor still in the practice of ophthalmology.

Physician pioneers technique offering higher perspective in surgery, outcomes.

The investigational therapy met all primary endpoints of absence of inflammation at both Day 8 and Day 15 for the treatment of pain and inflammation following cataract surgery.

Amid a pandemic, the Glaucoma Research Foundation is holding its annual gala online, funding aspirations for a glaucoma-free world with a goal of raising $1 million.

Cynthia Matossian, MD, FACS, ABES, continues her discussion on MGD treatment by explaining why it's important for patients to understand that MGD and dry eye are lifelong, chronic conditions requiring regular maintenance and monitoring.

Sometimes, physicians may find that falling behind is the right thing to do.

Neurophth Therapeutics, Inc (Neurophth) and AAVnerGene Inc have announced the launch of a strategic partnership that will grant Neurophth global rights to mutually select adeno-associated virus (AAV) capsids for the creation of the next-generation ophthalmic gene therapy.

Bausch + Lomb has enrolled 599 participants in the first of two Phase 3 studies evaluating perfluorohexyloctane as a first-in-class investigational drug to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction.

Higher levels of 3 macular pigments minimize risk of age-related disease.

A device developed by an Israeli startup was implanted in the eye of a patient, enabling him to recognize his family and read words.

Study evaluates the impact of surgical procedure on visual outcomes in patients.

See what ranked most popular in our top 10 stories of 2020.

A new gene therapy for this patient population targets the ND4 gene mutation.

Check out the latest cartoon!

Amid ramped up production of vaccines, CARES Act gives FDA power to head off potential drug shortfalls. Prevent Blindness is urging the FDA to use its authority to ensure TED treatment drug supply isn’t interrupted.

BIGH3 is an extracellular matrix protein that can act in an autocrine, paracrine manner.

Spaceflight-associated neuro-ocular syndrome a potential challenge during long missions.

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Amydis announced the successful completion of a pre-investigational new drug (IND) meeting with the FDA for its candidate AMDX-2011P, a small-molecule retinal tracer that targets amyloid beta to diagnosis amyloid angiopathy.

In a letter to Health and Human Services Secretary Alex Azar, the American Hospital Association is urging the federal government to expedite the administration of COVID-19 vaccines.

Imaging ciliary muscle details mechanism of accommodation, effects of aging .